
Opinion|Videos|April 3, 2025
Advancing From Topicals to Systemic Treatment in Psoriasis Management
Panelists discuss how undertreatment in psoriasis persists despite expanded therapeutic options due to multiple barriers including limited physician awareness of disease impact, insurance restrictions, socioeconomic disparities, patient concerns about medication safety, inadequate screening for comorbidities like psoriatic arthritis, outdated treatment paradigms, health care access challenges, and the failure to recognize that even limited disease in high-impact areas may warrant systemic therapy.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What are some potential reasons for undertreatment in psoriasis despite a wide range of available treatment options in recent years?
Advertisement
Related to this article

Children receiving 50 nmol PVX108 increased their tolerated peanut dose 2.4-fold, with no treatment-related anaphylaxis in the phase 2 trial.

Ackerman and Bunick review 52-week AMETHYST data for litifilimab in refractory cutaneous lupus and make the case for dermatology-led CLE care.

Lawrence Eichenfield, MD, discusses phase 2 nemolizumab data in children aged 2 - 11 with atopic dermatitis, from caregiver-rated itch to sleep gains.

In this Q&A, Jennifer K. Priessnitz, MD, explains why FAERS reporting proportions should not drive biologic selection and what data are needed next.

At ACAAI 2026, Jennifer Priessnitz, MD presented data which found omalizumab had the highest anaphylaxis reporting proportion among 7 respiratory biologics.

Pooled, blinded week 12 data from the phase 2 RENEW trial showed FVC improvement in 8 of 24 patients with IPF and no treatment-related serious AEs.

Ankeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.
Advertisement
Advertisement
Trending on HCPLive
1
Single Annual Injection Produces Significant and Sustained Lp(a) Reductions
2
Ruvonoflast Reduces hsCRP, Inflammation, CVD Risk With Downstream Effects
3
One COPD Exacerbation Is Too Many: Vickram Tejwani, MD
4
Monthly PVX108 Raises Peanut Tolerance in Children, With Brian Vickery, MD
5

